期刊文献+

不同来源的CC类趋化因子5对人乳腺癌MCF-7细胞侵袭能力影响及其作用机制研究

Effect of chemokine CCL5 of different sources on the invasion of human breast cancer MCF-7 cells and its mechanism
下载PDF
导出
摘要 目的 观察不同来源的CC类趋化因子5(CC chemokine ligand 5,CCL5)对人乳腺癌细胞侵袭能力影响并探讨其作用机制.方法 CCL5特异性siRNA慢病毒载体转染人乳腺癌MCF-7细胞,分别用RT-PCR和Western Blot检测细胞CCL5 mRNA和蛋白表达水平,并用细胞侵袭实验检测转染前后细胞侵袭能力的变化.同时,以不同浓度的外源性rhCCL5 (recombinant human CCL5) 作为趋化因素,用细胞侵袭实验检测MCF-7细胞侵袭能力及CC类趋化因子受体5(CCR5)单克隆抗体细胞侵袭能力的影响.结果 CCL5-siRNA慢病毒载体感染可有效降低CCL5 在MCF-7细胞内的表达,细胞的侵袭指数无明显改变,干扰组和阴性对照组侵袭指数差异无统计学意义(P〉0.05).rhCCL5可以明显诱导MCF-7细胞的侵袭(P〈0.05),并且呈浓度依赖趋势;但是这种诱导作用可以部分地被CCR5单克隆抗体阻断,阻断前后细胞的侵袭指数分别为(7.51±0.77)和(3.34±0.51),差异有统计学意义(P〈0.05).结论 细胞内表达的CCL5水平变化对乳腺癌细胞MCF-7的侵袭能力没有影响,而外源性CCL5 可以明显增强MCF-7细胞的侵袭,其机制之一可能是通过与细胞表面的CCR5受体结合. Objective To examine the effects of the intrinsic and extrinsic CC ehemokine ligand(CCLS) on the invasion of human breast cancer cells MCF-7 and the possible mechanisms. Methods CCL5 specific siRNA was transfected into MCF-7 cells. RT - PCR and Western Blot analysis were used to detect the expression levels of CCL5 in MCF-7 cells. The cell invasion assay was employed to evaluate the invasion ability of the transfected and non - transfected cells. MCF-7 cells ( with or without the treatment of anti - CCR5 antibodies ) were induced by recombinant human CCL5 ( rhCCL5 ) of different concentration and the effect of rhCCL5 on the invasion of MCF-7 cells was detected by using the cell invasion assay as well. Results CCI_5 - specific siRNA transfection could attenuate the expression level of CCL5 in MCF-7 cells effectively(P 〈0.05) ,while the cell invasive ability of these transfected cells were not declined accordingly ( P 〉 0.05 ). rhCCL5 could effectively strengthen the invasion ability of MCF-7 cells in a concentration - dependent manner(P 〈 0.05 ). The inducing effect of rhCCL5 could be partly blocked by anti - CCR5 antibodies and the invasion index was decreased from 7.51 ± 0.77 to 3.34 ±0.51 ( P 〈 0.05). Concimion The intrinsic CCL5 expression level in MCF-7 ceils had not evident effect on the invasive ability of MCF-7 cells,while the extrinsic CCL5 could enhance the invasion of MCF-7 cells effectively.
出处 《临床外科杂志》 2010年第9期600-602,共3页 Journal of Clinical Surgery
基金 湖北省卫生厅资助项目(编号:JS3A14)
关键词 乳腺癌 MCF-7细胞 CC类趋2化因子5 CC类趋化因子受体5 侵袭 breast cancer MCF-7 cells CC chemokine ligand CCRS invasion
  • 相关文献

参考文献8

  • 1Kudo T,Lu H,Wu JY,et al.Regulation of RANTES promoter activation in gastric epit helial cells infected with Helicobacterpylori[J].Infect Immun,2005,73(11):7602-7612.
  • 2Eissa SA,Zaki SA,El-Maghraby SM,et al.Importance of serum IL-18 and RANTES as markers for breast carcinoma progression[J].Egypt Natl Canc Inst,2005,17(1):51-55.
  • 3Yaal-Hahoshen N,Shina S,Leider-Trejo L,et al.The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients[J].Clin Cancer Res,2006,12(15):4474-4480.
  • 4Appay V,Rowland-Jones SL.RANTES:a versatile and controversial chemokine[J].Trends Immunol,2001,22(2):83-87.
  • 5匡军秀,王卫星,孙圣荣,王万荣.人CCL5基因RNA干扰慢病毒载体的构建[J].中华实验外科杂志,2009,26(2):174-176. 被引量:4
  • 6姚晓莉,童鹤翔,涂毅,姚峰,王卫星,孙圣荣.CCL5及其受体在乳腺癌组织中的表达及其意义[J].中华实验外科杂志,2007,24(5):590-592. 被引量:15
  • 7Elina A,Galia L,Sima S,et al.The CC chemokine RANTES in breast carcinoma progression:regulation of expression and potential mechanisms of promalignant activity[J].Cancer Res,2002,62(4):1093-1102.
  • 8Karnoub AE,Dash AB,Vo AP,et al.Mesenchymal stem cells within tumour stroma promote breast cancer metastasis[J].Nature,2007,449(7162):557-563.

二级参考文献13

  • 1姚晓莉,童鹤翔,涂毅,姚峰,王卫星,孙圣荣.CCL5及其受体在乳腺癌组织中的表达及其意义[J].中华实验外科杂志,2007,24(5):590-592. 被引量:15
  • 2Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 2007,449 : 557 -563.
  • 3Manes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med,2003 ,198 :1381-1389.
  • 4Jayasinghe MM, Golden JM, Nair P, et al. Tumor-derived CCL5 does not contribute to breast cancer progression. Breast Cancer Res Treat, 2008,111:511-521.
  • 5Adler EP, Lemken CA, Katchen NS, et al. A dual role for tumor-derived chemokine RANTES ( CCL5 ). Immunol Lett, 2003,90: 187- 194.
  • 6Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res ,2001,7:285-289.
  • 7Azenshtein E, Luboshits G, Shina S, et al. The CC ehemokine RANTES in breast carcinoma progression:regulation of expression and potential mechanisms of premalignant activity. Cancer Res, 2002,62 : 1093-1102.
  • 8Vaday GG, Peehl DM, Kadam PA, et al. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate,2006,66:124-134.
  • 9Sugasawa H, Iehikura T, Tsujimoto H, et al. Prognostic significance of expression of CCLS/RANTES receptors in patients with gastric caneer. J Surg Oneol,2008,97:445-450.
  • 10Lavergne E, Combadiere C, Iga M, et al. Intratumoral CC ehemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immuno1,2004 ,173 :3755-3762.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部